Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Core Viewpoint - Erasca, Inc. is participating in the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its focus on therapies for RAS/MAPK pathway-driven cancers [1] Company Overview - Erasca is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies specifically for patients with RAS/MAPK pathway-driven cancers [3] - The company was co-founded by pioneers in precision oncology and RAS targeting, aiming to create novel therapies and combination regimens to effectively shut down the RAS/MAPK pathway [3] - Erasca has developed one of the most comprehensive pipelines focused on the RAS/MAPK pathway in the industry, supported by a scientific advisory board of leading experts [3] Event Participation - Management will present at the conference on January 14, 2025, at 9:45 am Pacific Time and will engage in one-on-one investor meetings [1] - A live audio webcast of the event will be available on Erasca's website, with an archived replay accessible for 30 days post-event [2]